Regulus Therapeutics Inc.
RGLS
Rank in Stocks
#17317
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Share Price
$8.16
Last synced: 2025-06-26
Market Cap
$234.57M
Change (1 day)
0.00%
Change (1 year)
-56.96%
Country
US
Trade Regulus Therapeutics Inc. (RGLS)
Category
Healthcare
Stock price history for Regulus Therapeutics Inc. (RGLS)
Highest end of day price: $18.90 on 2024-08-01
Lowest end of day price: $25.97 on 2018-04-01
Lowest end of day price: $25.97 on 2018-04-01
Stock price history of Regulus Therapeutics Inc. from 2018 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2024 | 115.52% |
| 2023 | 128.77% |
| 2022 | -59.49% |
| 2021 | -66.20% |
| 2020 | -18.96% |
| 2019 | 28.12% |
| 2018 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $515.00 | 20.82% |
US
|
|
| $245.84 | 794.29% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $876.95 | 5.06% |
NL
|
|
| $752.63 | 7.37% |
CH
|
